ÄÉÃ׶þÑõ»¯¹è(SiO2),nano-silica(SiO2)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« 5ä庺·À¼º¼×ËØ,5-bromotetrandrineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±ÇÑÊÖ×Áö,nasopharyngeal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌØÕ÷Ñ¡È¡,feature selectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹Ü°©,Esophageal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂãСÊó,nude miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÓÈÈζÈ,Heating TemperatureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÖ×Áö/Ò©ÎïÁÆ·¨,stomach neoplasms/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙÑùÄÒÐÔ,adenoid cysticÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÖÀà¹æÔò,classification ruleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« siRNA,small interfering RNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¦Æ¶Ñª²¡¶¾,chicken anemia virusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʵÌåÖ×Áö,solid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Çú¹Å¾úËØA,trichostatin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈâÁöÑù°©,sarcomatoid carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNA½áºÏµ°°×ÖÊÀà,DNA-binding proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö΢»·¾³,Tumor microenvironmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¸Âö³å,Steep pulseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á×Ëáø»îÐÔ,phosphatase activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×È¥ÒÒõ£»¯Ã¸ÒÖÖƼÁ,Histone deacetylase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÖÜÆÚµ°°×B1,Cyclin B1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÔöÖ³ºË¿¹Ô­,PCNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×µ°°×΢Çò,albumin microspheresÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©Ï¸°ûÖê,lung cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÉãÈ¡,Cellular uptakeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MVD,microvessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì©°²ÊÐ,Taian CityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÂÓàÊÐ,Xinyu cityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BGC-823ϸ°û,BGC-823 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß·¢Çø,high incidence areaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÈÉñ¾­ÇÖÏ®,perineural invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼à²â×ÊÁÏ,monitoring dataÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÒ©ÄÍÒ©»ùÒò,multidrug resistance geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó¤¶ùË«Æç¸Ë¾ú,bifidobacterium infantisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©ÐÔ¶ñ²¡ÖÊ,cancer cachexiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÜÌåÏÔÏñ,Receptor imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´óãëºÓ,Dawen RiverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÖ×ÁöÆÁÕÏ,blood-tumor barrierÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·¦ÑõÏÔÏñ,hypoxia imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·´ÒåÏÔÏñ,antisense imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« L-°±»ùËáÑõ»¯Ã¸,L-amino acid oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³É¿×,pore-formingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »î»¯µ°°×-1,activator protein-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÏÔÏñ,Tumor imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Apoptin»ùÒò,apoptin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÆÖ²,Neoplasm transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­ß²ßø¢ù,Protoporphyrin ¢ùÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µòÍöËØ»ùÒò,Apoptin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö·¦Ñõ,tumor hypoxiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙ²¡¶¾¸ÐȾ,adenovirus infectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸±Ö×Áö×ÛºÏÕ÷,paraneoplastic syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éù¶¯Á¦Ñ§ÁÆ·¨,sonodynamic therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ûà×à¤ÍÑ°±Ã¸»ùÒò,cytosine deaminase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« p53mRNA,p53 mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉàÁÛ״ϸ°û°©,tongue squamous cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« F10»ùÒò,F10 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÈͨµÀ×è¶Ï¼Á,chloride channel blockerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßÄÚº­É¸Ñ¡,high content screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö÷¶¯°ÐÏò,Active targetingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SGC7901/VCRϸ°û,SGC7901/VCR cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·´ÒåºËËá¼¼Êõ,antisense nucleic acid technologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èí×éÖ¯Ö×Áö,soft tissue neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯¼äÖ²Èë,interstitial implantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¤ºóÖ¸±ê,Prognostic factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û½Çµ°°×18,cytokeratin 18Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« DADS,diallyl disulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹ÓÕ±äÒ©,antimutagenic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« hTRT»ùÒò,hTRT geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Ä-°±»ùÒÒõ£±ûËá,¦Ä-aminolevulinic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ÷¹Ù¼ÁÁ¿,Organ DoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö×Ó°ÐÏòÖÎÁÆ,Molecular targeted therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×ÍÑÒÒõ£Ã¸ÒÖÖƼÁ,Histone Deacetylase InhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö·ÖÀà,tumor classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« L-meq»ùÒò,L-meq geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ä½Ó±ê¼Ç,indirect labelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȱÑõ·´Ó¦Ôª¼þ,hypoxia response elementsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹²Í¬ÅàÑø¼¼Êõ,coculture techniquesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöѪ¹Ü,Tumor vesselÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÁÑÍö,mitotic cell deathÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÔ¤·À,cancer preventionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ü½»F344,inbred F344Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Egr-1»ùÒò,Egr-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« S-180ÈâÁö,S-180 sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˺ìϸ°ûĤ,human erythrocyte membraneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EhrlichÁö,Ehrlich tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´úл»î»¯,metabolic activationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½üºìÍâ¼¼Êõ,NIR technologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¬Êϸ¹Ë®Áö,ehrlich ascites tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PRL-3,PRL-3 GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ôɱ»ùÒòÁÆ·¨,Suicide Gene TherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒìÖÖ¿¹Ô­,XenoantigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ßÅßá3-²Ýõ£°·ÑÜÉúÎï,derivative of indol-3-glyoxylic acid amideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« S180ºÉÁöСÊó,S180 tumor-bearing miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×ÒÒõ£»ùתÒÆø,Histone acetyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÇÖϮתÒÆ,Tumor invasion and metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÃâÒßÌÓÒÝ,tumor immune escapeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áöϸ°ûǨÒÆ,Tumor cell migrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ°©Ï¸°ûϵ,gastric cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÏÙ°©A549ϸ°û,lung adenocarcinoma cell line A549Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« H-ras»ùÒò,H-ras geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 1 2 3 4 5 6 7 8 ÉÏÒ»Ò³